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arms were compared: cohort A patients (high-risk) treated by either TAVR (n149) or
surgical aortic valve replacement (SAVR, n138); and cohort B patients (considered
inoperable) treated by either TAVR (n72) or medical therapy only (MedTx, n95).
Results: In the total group of patients included in the PARTNER trial who underwent
TAVR, those having no COPD (n1096) and non-O2-dep COPD (n627) had better
1-year survival than did O2-dep COPD patients (n215). (Table) O2-dep COPD patients
who underwent TAVR and survived for 1 year had relatively low rates of high functional
class (NYHA class I/II): 79.2% of cohort A patients; 52.4% of cohort B. There were no
differences in baseline characteristics between the TAVR and control groups in the
different subgroups evaluated. In cohort A patients, 1-year outcomes did not differ
significantly between TAVR and SAVR. In cohort B patients, TAVR, compared to
MedTx, improved 1-year survival free of hospitalization but not 1-year survival. (Table)
Conclusions: Patients with severe COPD and severe AS are at higher risk for worse
clinical outcome and lower survival. In COPD patients, TAVR had better outcome than
did medical therapy but showed no benefit over SAVR.
All TAVR patients COPD patients (TAVR vs. control)
No
COPD
n1096
non-O2dep
COPD
n627
O2 dep
COPD
n215
p
Value
TAVR
n149
SAVR
n138
p
Value
TAVR
n72
MedTx
n95
p
Value
1-year survival
(%)
85.0 84.1 76.9 0.02 75.0 73.1 0.60 62.5 47.8 0.12
1-year survival
free from
hospitalization
(%)
79.2 78.3 69.7 0.01 65.5 63.0 0.57 51.4 30.1 0.03
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Background: The PARTNER Trial demonstrated that transcatheter aortic valve replace-
ment (TAVR) in high surgical risk patients with aortic stenosis was non-inferior to
surgical AVR. Whether there are gender-specific differences in the application of TAVR
to this high-risk population are unknown.
Methods: Patients enrolled in the high-surgical risk cohort of the PARTNER Trial
(Cohort A) were included in this analysis (n697). Gender-specific differences in baseline
characteristics and outcomes at 2 years of follow-up were compared by randomized
treatment assignment.
Results: Despite greater age (84.9 vs. 83.4, p0.01), and slightly higher median STS
scores (11.1 vs. 11.0, p0.03), women (n298) had a lower prevalence of important
comorbidities, including diabetes (35.6% vs. 45.6%, p0.01), smoking history (33.2% vs.
60.7%, p0.001), coronary artery disease (64.4% vs. 83.7%, p0.001), prior CABG
(19.8% vs. 60.4%, p0.001), peripheral vascular disease (36.4% vs. 46.9%, p0.01), and
chronic kidney disease (11.7% vs. 23.9%, p0.001). There were no differences in
outcomes at 30 days between TAVR and surgery in women; among TAVR patients, there
were similar rates of both mortality (4.1% vs. 3.0%, p0.58) and stroke (5.5% vs. 4.0%,
p0.52) in women compared to men. Compared to surgery, women undergoing TAVR
had better one (18.5% vs. 29.5%, p0.02) and 2-year (28.6% vs. 38.6%, p0.05)
survival, whereas, among men, there was no difference at either one (28.5% vs. 25.2%,
p0.67) or 2 years (37.5% vs. 32.1%, p0.43). Compared to surgery, women undergoing
TAVR had higher stroke rates at 1 year (7.1% vs. 0.7%, p0.01); this difference was not
seen in men (5.3% vs. 5.0%, p0.90). There was a significant treatment-gender
interaction for mortality and stroke at 1 but not 2 years, with no significant interactions for
other outcomes.
Conclusions: Gender-specific differences in outcomes (beyond 30 days) were observed
among randomized patients in PARTNER suggesting TAVR may be the preferred
therapy among women. Further investigation is required to determine whether this benefit
can be attributed specifically to gender, or whether other factors may be involved.
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Background: Female sex is associated with adverse outcomes following conventional
aortic valve replacement. We investigate gender differences following transcatheter aortic
valve implantation (TAVI) in the UK’s National Institute for Cardiovascular Outcomes
Research (NICOR) TAVI Registry.
Methods: Retrospective analysis of 1627 patients enrolled in a UK multicentre registry
from January 2007 to December 2010. TAVI was conducted via transfemoral, transapical,
subclavian/transaxillary and transaortic access routes with implantation of Medtronic
CoreValve ReValving System®, Edwards SAPIENTM and SAPIEN XTTM devices.
Results: TAVI was performed in 756 (46.5%) females and 871 (53.5%) males aged
82.66.8 years and 80.87.6 years respectively. Females had a higher peak aortic
gradient (84.428.6mmHg v 76.624.5mmHg; p0.001) and smaller aortic annulus
diameter (21.12.8mm v 23.03.1mm; p0.001). Men had greater prevalence of type
II diabetes (23.9% v 19.2%; p0.021), poor left ventricular systolic function (11.9% v
5.5%; p0.001), three vessel coronary artery disease (19.4% v 9.2%; p0.001), left main
stem disease (8.0% v 3.2%; p0.001), previous myocardial infarction (29.5% v 13.0%;
p0.005), peripheral vascular disease (32.4% v 23.3%; p0.001) and higher logistic
EuroSCORE (21.814.2% v 21.013.4%; p0.046). Kaplan-Meier mortality at 30 days was
6.3% (95% CI 4.3% to 7.9%) in women and 7.4% (5.6% to 9.2%) in men. At 6 months, 14.1%
(11.5% to 16.7%) and 16.6% (14.0% to 16.6%) respectively. At 1 year 21.9% (18.7% to
25.1%) and 22.4% (19.4% to 25.4%) respectively. There was no difference in mortality:
p0.331 by log-rank test; hazard ratio for women 0.911 (0.754 to 1.100). There was no
difference in device success rate (96.6% in women v 96.4% in men; p0.889) or cerebro-
vascular event rate at 30 days (3.8% v 3.7%; p0.962). However, women had significantly
more major vascular complications than men (7.5% v 4.2%; p0.004).
Conclusions: Despite a higher risk profile in males there was no difference in mortality,
procedural success or cerebrovascular event rate between genders. However, women had
almost twice the rate of major vascular complications compared with men.
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Background: Background Paravalvular regurgitation (PVR) after transcatheter aortic
valve replacement (TAVR) is associated with adverse outcomes. Studies evaluating the
utility of three-dimensional echo (3DE) are limited. We performed a retrospective analysis
using 3DE-derived annular measurements and evaluated their ability to predict PVR.
Methods: 58 TAVR patients were evaluated: 35 patients who receive a post-dilatation for
paravalvular regurgitation (PD) and 23 who did not (NoPD). Intra-procedural trans-
esophageal echocardiography was performed with both two-dimensional (2DE) and 3DE
imaging. PVR areas seen on a short axis view were measured immediately following
deployment. Pre-TAVR annular dimensions included the sagittal 2DE annular diameter
and 3DE measurements of: minimal diameter, maximal diameter, mean diameter, average
diameter and area. A cover index was calculated using these diameters. An area cover
index was also calculated using nominal areas of the THV and the 3DE.
Results: PD patients were more often male (p0.01) and had larger BSA (1.83 0.24
vs. 1.67 0.23 m2, p0.013) and a higher annular eccentricity index (13.6 5.1 vs.
8.01 5.3, p0.001). Following TAVR, PD patients had larger PVR areas immediately
following deployment (40.3 17.1 vs. 15.4 14.2mm2, p0.0001). These patients had
a lower cover index irrespective of the annular diameter used (Table). All measurements
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were linearly related to PVR (Table)however the highest correlation with the severity of
PVR was seen with the maximum diameter (r20.48, p0.001), mean diam-
eter(r20.47, p0.0001), average diameter (r20.48, p0.0001) or the annular area
(r20.48, p0.0001).
Conclusions: This study demonstrates that 3DE measurements of the aortic annulus are
feasible and are better predictors of PVR after TAVR than 2D sagittal diameter and should
be incorporated into the algorithm for balloon-expandable transcatheter valve sizing.
Comparison of 2DE and 3DE Measurements
Cover Index NoPD (n23) PD (n35) p-value
r2 for linear
measure
2DE Sagittal 10.14 4.02 6.89 3.24 0.002 0.26
(p  0.001)
3DE Minimum 16.19 6.39 10.88 4.91 0.001 0.36
(p0.0001)
3DE Maximum 8.67 7.87 -2.74 6.50  0.001 0.48
(p0.0001)
3DE Mean 12.44 6.65 4.07 4.71  0.001 0.47
(p0.0001)
3DE Average 11.50 6.11 2.68 4.93  0.001 0.48
(p0.0001)
3DE Area 23.09 10.32 7.91 9.14  0.001 0.48
(p0.0001)
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Background: Despite excellent outcome after transcatheter aortic valve implantation
(TAVI), paravalvular leaks may occur. Objective of this study was to evaluate annulus
sizing by 3-D computed tomography (CT) for prediction of paravalvular leaks after TAVI,
and to compare CT with transesophageal (TEE) and intracardiac echocardiography (ICE).
Methods: In 88 patients (mean, 83yrs) with severe aortic stenosis who underwent TAVI,
transesophageal (TEE), intracardiac echocardiography (ICE) and ECG-gated CT-
Angiography were performed before device implantation. Two-(ML/AP), three-annulus
diameter (RC/LC/NC) and the annulus area were measured on CTA. “Undersizing” was
defined as CT annulus–prosthetic heart valve (PHV) size; “annulus eccentricity” as
AP/ML-annulus diameter ratio. Post-procedural echocardiography was performed imme-
diately after, and at 1, 3,6, 12 and 24 month after the procedure and severity of
paravalvular leaks graded.
Results: Of 88 implanted prosthetic heart valves (PHV) 22 (25%) had none, 46 (52.3%)
mild, 11 (12.5%) mild-to-moderate, 9 (10.2%) moderate or moderate-to-severe, and 0%
severe leaks. Both TEE and ICE measured smaller mean annulus diameters than CT
(mean:-2,84mm and -2.19mm, resp., p0.01). Overall, 53% of PHV were undersized, in
only 3/22 (14%) patients with no leaks and in 35/66 (53%) with leaks. Undersizing was
higher in those with leaks as compared to those without (1mm vs 0.2mm, p0.01). No
difference between mild and moderate-to-severe (1mm vs. 1.2mm, p0.64) leaks were
found for the mean of 3-annulus diameters. The annulus area undersizing was higher in
patients with leaks than in those without (0.44cm2 vs 0.14cm2, p0.05), however the
annulus eccentricity index was not different (0.82 vs. 0.82, p0.06). If applying the 3-
instead of 2-diameter annular CT measurements, 4 (5%) patients without leaks and 2 (2%)
with leaks were reclassified as not-undersized and undersized, respectively.
Conclusions: PHV undersizing relative to CT annulus dimensions is associated with
paravalvular leaks after TAVI, but not annulus eccentricity. Three-diameter annulus
sizing by CT may be more accurate than the two-diameter method.
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Background: To develop computed tomography (CT) sizing guidelines for transcatheter
aortic valve replacement (TAVR). CT annular measurements are predictive of paraval-
vular regurgitation post TAVR; a predictor of mortality and morbidity.
Methods: The Vancouver CT sizing guidelines aim to ensure routine transcatheter heart
valve (THV) over sizing of the aortic annulus (range:1-20%, target 10-15%). Percentage
of over sizing is defined as (THV external area/annular area-1) x 100. 120 consecutive
patients underwent CT prior to TAVR with balloon expandable valves using transesoph-
ageal echocardiography (TEE) sizing recommendations. The Vancouver CT sizing
guidelines recommended prosthesis size was compared to the actual size implanted.
Results: As compared to TEE sizing recommendations, the Vancouver CT sizing
guidelines recommended a larger valve in 33.3% (40/120), no change in valve size in
55.8% (67/120) and a smaller valve in 10.8%(13/120). In patients where CT guidelines
would have recommended a larger valve, the incidence of at least moderate paravalvular
regurgitation was 25% (10/40), compared to only 4.5% (3/67, p0.01) when both TEE
and CT guidelines were in agreement. Traditional TEE sizing methods resulted in
33.3%(40/120) of valves being under sized (THV areaCT annular area) with a mean
annular over sizing of 9.417.4% (range: -21.5 to 65.9%) without annular rupture. In
contrast, the Vancouver CT sizing guidelines results in mean annular over sizing of
13.98.0% (range: 1.3-29.8%).
Conclusions: The Vancouver CT sizing guidelines enable standardized moderate over
expansion of the annulus that is likely to result in significantly lower rates of paravalvular
regurgitation.
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Background: Transcatheter aortic valve-in-valve (VIV) implantation is an emerging
therapeutic alternative for patients with failed surgical bioprosthesis and may obviate the
need for a redo surgery. We aimed to evaluate the clinical results of this technique using
a large worldwide registry.
Methods: The registry included 416 patients with degenerated aortic bioprosthetic valves
(age 77.7  9.7 years; 55.3% men) from 54 cardiac centers. The mode of failure was
stenosis (n168, 40.4%), regurgitation (n125, 30%), and combined stenosis and
regurgitation (n123, 29.6%). Implanted devices were Edwards SAPIEN (n225),
CoreValve (n190) and Melody (n1).
Results: Adverse procedural outcomes included 11.1% device malposition and 1.9%
ostial coronary obstruction. Post-procedure, valve maximum / mean gradients were 28.5 
14.3 mmHg / 16.1  9.0, respectively. Independent predictors for high post-
procedural gradients (mean 20 mmHg) were baseline bioprosthesis stenosis [vs.
regurgitation, odds ratio (OR), 6.33, p  0.001)] and the use of the Edwards SAPIEN
device (OR 2.1, p 0.008). At 30-day follow-up, all-cause mortality was 7.8% and
87.5% of patients were at New York Heart Association functional class I/II. One-year
survival was 82.6%. The strongest independent predictor for 1-year mortality post
VIV was baseline bioprosthesis stenosis (vs. regurgitation, OR 3.7, p0.003).
Conclusions: The VIV procedure is clinically effective in most patients, with 1-year
results comparable with other TAVR cohorts. Baseline bioprosthetic stenosis is the
strongest predictor for both elevated post-procedural gradients and 1-year mortality.
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Background: A novel, innovative transapical aortic valve implantation (TA-TAVI)
system completed enrollment (n90) in two pre-market studies. The TA device received
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